BlackRock Health Sciences Term Trust (NYSE:BMEZ) has seen its discount to net asset value narrow some from our last update, though the discount still looks appealing today. The biotech space, which comprises a significant portion of BMEZ's portfolio, has been performing better so far to start 2024. However, that was after significant losses in most of the last three years, where the biotech space saw significant declines overall. Besides the healthcare portfolio that BMEZ invests in, they also utilize a covered call writing strategy and invest in private investments to help differentiate the fund.